Lost in translation: epidemiology, risk, and Alzheimer disease
- PMID: 20065137
- PMCID: PMC2806646
- DOI: 10.1001/archneurol.2009.311
Lost in translation: epidemiology, risk, and Alzheimer disease
Abstract
There is increasing emphasis on interdisciplinary “translation” in biomedical research. A major push towards prevention of Alzheimer's Disease is spawning translational research that should span basic, clinical, and population investigations. Epidemiological studies, which address our understanding of risk and protective factors for disease at the population level, are contributing less than they could to translational research. In part, this is because the key concept of risk is being “lost in translation,” muddling interpretations and leading to interdisciplinary frustrations. Two epidemiologists offer a framework for resolving some of the confusion.
References
-
- Zerhouni E. Translational and clinical science – time for a new vision. N. Engl. J. Med. 2005;353:1621–1623. - PubMed
-
- Hodes RJ. Public funding for Alzheimer disease research in the United States. Nature Medicine. 2006;12:770–773. - PubMed
-
- Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women. JAMA. 2002;288:2123–2129. - PubMed
-
- Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. Women's Health Initiative Memory Study. JAMA. 2004;291:2947–2958. - PubMed
-
- ADAPT Research Group Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800–1808. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
